PHELAN-McDERMID SYNDROME · White paper
Phelan-McDermid Syndrome Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About phelan-mcdermid syndrome — and why its trials are hard
Phelan-McDermid Syndrome (PMS), also called 22q13.3 deletion syndrome, is a rare neurodevelopmental disorder caused by terminal deletions of chromosome 22q13 or pathogenic variants in the SHANK3 gene, which is essential for synapse formation and function. Estimated to affect roughly 1 in 8,000 to 1 in 15,000 individuals, PMS presents with global developmental delay, intellectual disability, absent or severely delayed speech, neonatal hypotonia, autism spectrum features (in about 75% of patients), seizures, sleep disturbance and altered pain sensitivity. Critically, there are no FDA-approved therapies that target the underlying cause of PMS; management is entirely symptomatic and off-label, using antipsychotics, antiepileptics and sleep aids to address behavior, seizures and insomnia. This makes PMS a paradigm of the rare-disease trial-design challenge: symptom heterogeneity, small and geographically dispersed patient populations, incremental and hard-to-measure developmental change, reliance on caregiver-reported outcomes, and strong placebo responses all complicate endpoint selection. Investigational SHANK3-directed and synaptic candidates (e.g. NNZ-2591, gene therapy) are advancing, but none is yet approved.
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in phelan-mcdermid syndrome development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| AMO-01 (mGluR5 modulator) — Phase 2 (Rugen/AMO) | Failed to show sufficient efficacy on cognitive/behavioral outcomes despite promising preclinical data | Weak translation from animal models; heterogeneous endpoints and small sample |
| Insulin-like growth factor-1 (mecasermin, IGF-1) — Pilot/controlled studies in PMS | Did not deliver consistent, replicable clinical benefit across social/behavioral endpoints | Small samples, variable response, and lack of validated sensitive outcome measures |
| Intranasal oxytocin — Controlled trials in PMS/ASD | Failed to show reliable improvement in social behavior over placebo | High placebo response and subjectivity of social-behavior assessments |
Choosing the right endpoint
Primary endpoints that matter in phelan-mcdermid syndrome trials
- Clinical Global Impression - Improvement (CGI-I) — Composite clinician/caregiver rating widely used in PMS trials; NNZ-2591 Phase 2 reported a mean CGI-I of ~2.4 (unverified)
- Vineland Adaptive Behavior Scales (VABS) — Caregiver-based measure of communication, daily living and social skills; sensitive to incremental developmental change in longitudinal designs
- Aberrant Behavior Checklist / Social Responsiveness Scale — Standardized behavioral endpoints; behavior fluctuates day to day, so caregiver diaries and repeated measures improve reliability
- Seizure frequency (diaries + EEG) — Objective anchor for a common PMS comorbidity; requires clear reduction criteria and EEG confirmation over adequate observation windows
- Motor / language milestones (e.g. Bayley Scales) — Track fine and gross motor and speech gains; improvements are gradual, favoring long-term follow-up and personalized endpoints
How iNGENū runs phelan-mcdermid syndrome trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
The full white paper: approved-product analyses, pivotal endpoints and trial-design strategy. Open-access · no sign-in.
Frequently asked questions
Phelan-McDermid Syndrome clinical trials — FAQs
Are there any FDA-approved drugs for Phelan-McDermid Syndrome?
What treatments are in development?
Why are PMS clinical trials so challenging to design?
Ready to discuss your phelan-mcdermid syndrome trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal